Authors
Chiwei Guo, Tiantian Geng, Luzhen Ye, Zhonghua Sun, Shujuan Zhao
Published in
Science progress. Volume 109. Issue 4. Pages 368504261501366. Epub Oct 19, 2026.
Abstract
ObjectiveInterleukin-23 (IL-23) inhibitors are widely used for psoriasis and inflammatory bowel disease, yet their long-term safety profiles require continual monitoring. This retrospective observational real-world study aimed to detect potential disproportionate reporting signals associated with tildrakizumab, risankizumab, and guselkumab using the FDA Adverse Event Reporting System (FAERS).MethodsAE reports for tildrakizumab, risankizumab, and guselkumab from Q3 2017 to Q3 2025 were retrieved from FAERS. Disproportionality analysis using reporting odds ratios (RORs) was performed, and reported adverse events were classified by system organ classes (SOCs).ResultsA total of 1124, 8574, and 14597 AEs were retrieved for the three IL-23 inhibitors, generating 42, 286, and 348 disproportionate reporting signals, and accumulating 23, 24, and 24 SOCs. Frequently reported AEs included drug ineffectiveness, psoriasis, injection-site reactions, and infections. Disproportionate reporting signals not listed in the current FDA-approved product label comprised cardiovascular events (e.g., myocardial infarction; tildrakizumab ROR = 6.45), malignancies (e.g., malignant melanoma; risankizumab ROR = 8.57), hepatobiliary disorders, and renal complications.ConclusionThese exploratory, hypothesis-generating disproportionate reporting signals may inform routine pharmacovigilance practice for IL-23 inhibitors, alongside well-established common reported events such as infections and systemic reactions. Further pharmacoepidemiologic studies are needed to validate these observations.
PMID:
42896048
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 19
- Comments 0